Development of prophylactic vaccines against HIV-1.

Journal article

The focus of most current HIV-1 vaccine development is on antibody-based approaches. This is because certain antibody responses correlated with protection from HIV-1 acquisition in the RV144 phase III trial, and because a series of potent and broad spectrum neutralizing antibodies have been isolated from infected individuals. Taken together, these two findings suggest ways forward to develop a neutralizing antibody-based vaccine. However, understanding of the correlates of protection from dis...

Expand abstract

Authors: Schiffner, T; Sattentau, Q; Dorrell, L

• Publication status: Published
• Journal: Retrovirology
• Volume: 10
• Issue: 1
• Pages: 72
• Publication date: 2013-01-01
• DOI: 10.1186/1742-4690-10-72
• EISSN: 1742-4690
• ISSN: 1742-4690
• Language: English
• Keywords: Drug Discovery; Acquired Immunodeficiency Syndrome; AIDS Vaccines; HIV Antibodies; Antibodies, Neutralizing; Humans; HIV-1; T-Lymphocytes, Cytotoxic; Clinical Trials as Topic